Peer Review reports
From: Axitinib as a third or further line of treatment in renal cancer: a single institution experience
Original Submission | ||
---|---|---|
12 Jan 2020 | Submitted | Original manuscript |
15 Mar 2020 | Reviewed | Reviewer Report - Petros Grivas |
15 Mar 2020 | Reviewed | Reviewer Report - NIKOLAOS GRIVAS |
14 Apr 2020 | Author responded | Author comments - Giorgos Tsironis |
Resubmission - Version 2 | ||
14 Apr 2020 | Submitted | Manuscript version 2 |
Publishing | ||
21 Apr 2020 | Editorially accepted | |
2 Jun 2020 | Article published | 10.1186/s12894-020-00618-1 |
You can find further information about peer review here.